Zydus Knocked Back On Farxiga In US As Brand Continues To Grow
US Court Finds Key Patent Is Not Invalid As Obvious
Executive Summary
Zydus Cadila has failed to prove to a US court that a US patent expiring in October 2025 that shields AstraZeneca’s Farxiga (dapagliflozin) SGLT2 inhibitor is obvious, keeping the firm’s proposed ANDA product off of the market for now.